Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30073511 | 1.00 | METAP2 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL20939018 | 1.00 | METAP2 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL29092524 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL29092526 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL30073441 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL22584143 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL20939258 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL22584145 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL22584146 | 0.93 | IDO1 (0.40) | METAP2IDO1TDO2NOS1DYRK1A | |
| SCHEMBL20939225 | 0.92 | METAP2 (0.37) | METAP2IDO1TDO2NOS1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2023-01-10 | — | — | US | claimed |
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-10-29 | — | — | US | claimed |
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2023-01-10 | — | — | US | disclosed |
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2023-01-10 | — | — | US | disclosed |
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-10-29 | — | — | US | disclosed |
| WO-2019076358-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339533-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | IDO1, TDO2, IDO2 | METAP2 735/4885IDO1 1/4885TDO2 2/4885 |
| US-11548868-B2 | Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof | IDO1, TDO2, IDO2 | METAP2 735/4885IDO1 1/4885TDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.